These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 19005269

  • 1. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C, Late Presenter Investigators.
    AIDS; 2008 Nov 30; 22(18):2461-9. PubMed ID: 19005269
    [Abstract] [Full Text] [Related]

  • 2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 30; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S, CoRIS-MD.
    PLoS One; 2006 Dec 20; 1(1):e89. PubMed ID: 17183720
    [Abstract] [Full Text] [Related]

  • 4. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
    Kaufmann GR, Khanna N, Weber R, Perrin L, Furrer H, Cavassini M, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Antivir Ther; 2004 Apr 20; 9(2):263-74. PubMed ID: 15134189
    [Abstract] [Full Text] [Related]

  • 5. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.
    HIV Med; 2007 May 20; 8(4):213-9. PubMed ID: 17461848
    [Abstract] [Full Text] [Related]

  • 6. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL.
    APMIS Suppl; 2003 May 20; (114):1-37. PubMed ID: 14626050
    [Abstract] [Full Text] [Related]

  • 7. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar 20; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

  • 8. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.
    Antivir Ther; 2008 Mar 20; 13(7):927-36. PubMed ID: 19043927
    [Abstract] [Full Text] [Related]

  • 9. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 10. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.
    Clin Infect Dis; 2008 Jan 15; 46(2):305-12. PubMed ID: 18171267
    [Abstract] [Full Text] [Related]

  • 11. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda.
    Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, Joffres M, Anema A, Cooper CL, Montaner JS, Mills EJ.
    AIDS; 2008 Nov 30; 22(18):2493-9. PubMed ID: 19005272
    [Abstract] [Full Text] [Related]

  • 12. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.
    AIDS; 2006 May 12; 20(8):1181-9. PubMed ID: 16691070
    [Abstract] [Full Text] [Related]

  • 13. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 14. Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.
    Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A.
    J Clin Virol; 2009 Nov 12; 46(3):290-4. PubMed ID: 19699675
    [Abstract] [Full Text] [Related]

  • 15. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J.
    Clin Infect Dis; 2007 Oct 01; 45(7):925-32. PubMed ID: 17806063
    [Abstract] [Full Text] [Related]

  • 16. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F, Mosam A, Henry LN, Chisholm JV, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C.
    AIDS; 2007 Jun 19; 21(10):1245-52. PubMed ID: 17545700
    [Abstract] [Full Text] [Related]

  • 17. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ.
    AIDS; 2007 Apr 23; 21(7):825-34. PubMed ID: 17415037
    [Abstract] [Full Text] [Related]

  • 18. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.
    Dronda F, Sobrino P, Hernández-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, Sanz J, Del Mar Alonso M, Labarga P, Bernal E, Moreno S, CoRIS.
    Curr HIV Res; 2011 Jun 23; 9(4):229-36. PubMed ID: 21631429
    [Abstract] [Full Text] [Related]

  • 19. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.
    HIV Med; 2008 May 23; 9(5):300-6. PubMed ID: 18400077
    [Abstract] [Full Text] [Related]

  • 20. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J, Asensi V, Cartón JA.
    AIDS; 2007 Apr 23; 21(7):835-43. PubMed ID: 17415038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.